Last 29 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 29.93 | — | 183.40 | 9.64 | 26.06 | — | 10.73 | 9.44 | 8.91 | 14.92 | 7.94 | 14.80 | 7.99 | 6.13 | 4.22 | 1.97 | 1.57 | 2.47 | — | — | — |
| — | — | +1608.8% | +2.1% | +192.3% | — | +35.2% | -36.2% | +11.5% | +143.5% | +88.3% | +650.4% | +409.8% | +147.6% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -310.8% | — | -193.8% | -143.8% | -833.8% | -295.4% | -100.6% | -64.9% | -50.5% | -45.8% | -93.3% | -49.2% | -40.3% | -30.3% | -21.0% | -13.9% | -62.9% | -110.0% | -351.8% | -104.8% | -54.8% |
| — | — | -92.7% | -121.5% | -1550.0% | -544.7% | -7.7% | -31.9% | -25.3% | -51.3% | -344.0% | -253.0% | +35.9% | +72.5% | +94.0% | +86.7% | -14.9% | — | — | +57.8% | +75.0% | |
| ROA | -138.5% | -40.8% | -32.8% | -28.4% | -33.8% | -36.2% | -39.3% | -41.3% | -33.2% | -29.3% | -63.9% | -38.5% | -32.3% | -23.1% | -16.1% | -11.0% | -50.4% | -58.9% | -27.7% | -12.8% | -8.2% |
| — | -12.7% | +16.4% | +31.1% | -1.9% | -23.3% | +38.5% | -7.1% | -2.7% | -27.2% | -297.8% | -249.9% | +35.9% | +60.8% | +41.9% | +14.1% | -518.9% | -970.7% | -21.4% | +73.0% | +87.9% | |
| ROIC | -239.1% | -106.7% | -87.6% | -78.5% | -97.8% | -68.2% | -69.5% | -59.6% | -45.8% | -61.4% | -154.7% | -76.4% | -54.9% | -34.6% | -21.8% | -15.7% | -75.8% | -163.6% | -36.6% | -16.4% | -174.5% |
| — | -56.5% | -26.1% | -31.6% | -113.4% | -11.0% | +55.1% | +22.0% | +16.4% | -77.4% | -608.5% | -387.6% | +27.6% | +78.8% | +40.3% | +4.3% | +56.6% | — | +90.9% | +77.4% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.47 | — | 24.30 | 2.21 | 5.47 | — | 2.17 | 0.14 | 0.09 | 0.09 | 0.08 | 0.10 | 0.07 | 0.11 | 0.08 | 0.06 | 0.06 | 0.05 | 0.22 | 7.00 | 0.03 |
| — | — | +1021.9% | +1514.8% | +6226.3% | — | +2695.0% | +35.1% | +19.8% | -15.7% | +3.1% | +60.7% | +15.7% | +109.6% | -65.6% | -99.1% | +82.5% | — | — | +253.7% | -27.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.18 | 3.05 | 4.73 | 7.41 | 3.18 | 2.86 | 3.82 | 2.33 | 3.49 | 2.89 | 3.27 | 4.03 | 7.98 | 4.99 | 4.94 | 4.78 | 6.52 | 2.83 | 0.71 | 0.13 | 2.26 |
| — | +6.6% | +23.9% | +217.4% | -9.0% | -1.0% | +16.7% | -42.1% | -56.3% | -42.1% | -33.8% | -15.7% | +22.4% | +76.3% | +596.1% | +3517.6% | +188.4% | +38.7% | -57.5% | -36.7% | -24.7% | |
| Quick Ratio | 3.18 | 3.05 | 4.73 | 7.41 | 3.18 | 2.86 | 3.82 | 2.33 | 3.49 | 2.89 | 3.27 | 4.03 | 7.98 | 4.99 | 4.94 | 4.78 | 6.52 | 2.83 | 0.71 | 0.13 | 2.26 |
| — | +6.6% | +23.9% | +217.4% | -9.0% | -1.0% | +16.7% | -42.1% | -56.3% | -42.1% | -33.8% | -15.7% | +22.4% | +76.3% | +596.1% | +3517.6% | +188.4% | +50.6% | -53.0% | -36.7% | -24.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BHVN stock.
Biohaven Ltd.'s current P/E is -4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Biohaven Ltd.'s business trajectory between earnings reports.